Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 2, 2008, Pages 188-194

  Azuma, Haruhito ^a   Sakamoto, Takeshi ^a   Kiyama, Satoshi ^a   Ubai, Takanobu ^a   Kotake, Yatsugu ^a   Inamoto, Teruo ^a   Takahara, Kiyoshi ^a   Nishimura, Yasuichiro ^a   Segawa, Naoki ^a   Katsuoka, Yoji ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Chemohormonal therapy; Etoposide; Fosfestrol; HRPC; Oral chemotherapy

Indexed keywords

ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FOSFESTROL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER TOXICITY; MALE; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIETHYLSTILBESTROL; DRUG RESISTANCE, NEOPLASM; DRUG TOXICITY; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 42049092408     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181595af6     Document Type: Article

References (20)

1. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098-1109.
2. Smith DC. Chemotherapy for hormone refractory prostate cancer. Urol Clin North Am. 1999;26:323-331.
3. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972-3982.
4. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer. 2002;94:1457-1465.
5. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (calgb 9583). J Clin Oncol. 2004;22:1025-1033.
6. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
7. Petrylak DP. The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol. 2006;8:S48-S55.
8. Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology. 2006;68:565-569.
9. Moore MJ, Osoba D, Murphy K, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol. 1994;12:689-694.
10. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997;15:3156-3163.
11. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
12. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group b 9182 study. J Clin Oncol. 1999;17:2506-2513.
13. Francini G, Petrioli R, Gonnelli S, et al. Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma. Cancer. 2001;92:1468-1474.
14. Morant R, Bernhard J, Maibach R, et al. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss group for clinical cancer research (sakk). Ann Oncol. 2000;11:183-188.
15. Boehmer A, Anastasiadis AG, Feyerabend S, et al. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience. Anticancer Res. 2005;25:4481-4486.
16. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-refractory prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol. 1996;14:1756-1764.
17. Kelly WK, Curley T, Slovrin S. Paclitaxel, estramustine phosphate and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001;19:44-53.
18. Nishimura K, Nonomura N, Yasunaga Y, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 2000;89:2570-2576.
19. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
20. Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920-928.